QPPV.COM KNOWLEDGE ASSESSMENT

Historical Signal Evaluation: Pioglitazone and Bladder Cancer

Test your understanding of the concepts covered by Historical Signal Evaluation: Pioglitazone and Bladder Cancer.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is unexplained haematuria relevant to risk minimisation for pioglitazone?

It is a clinically relevant symptom that may warrant investigation for underlying urinary-tract disease It proves that pioglitazone has already caused bladder cancer It is an expected harmless effect of all glucose-lowering medicines It removes the need to consider smoking or previous cancer history

Question 2 of 10 What is the appropriate interpretation of a non-statistically significant association in a study with few bladder-cancer events?

It proves the absence of a clinically relevant risk It may reflect limited power and should be interpreted with the estimate and confidence interval It proves that all positive studies are biased It demonstrates that randomisation failed

Question 3 of 10 Which regulatory response best reflects the article's description of the pioglitazone case?

Universal withdrawal solely because any bladder cancer occurred during treatment No action until a definitive human mechanism was demonstrated Targeted warnings and restrictions focused on active or previous bladder cancer, unexplained haematuria and individual risk factors Removal of all diabetes treatments from patients with cancer risk factors

Question 4 of 10 Why can a numerically higher number of bladder-cancer cases in a randomised trial still leave substantial uncertainty?

Randomisation increases confounding when cancer events are rare Rare outcomes may produce unstable estimates and limited statistical power Randomised trials cannot compare treatment groups A numerical difference is irrelevant unless all patients develop the event

Question 5 of 10 What is the most appropriate interpretation of bladder tumours observed in male rats exposed to pioglitazone?

They establish that pioglitazone causes bladder cancer in humans They provide biological concern, but human relevance requires further evaluation They can be disregarded because animal findings never inform pharmacovigilance They prove that urinary crystals are the mechanism of human bladder cancer

Question 6 of 10 What is the principal purpose of product-information changes in a complex safety signal such as this one?

To reproduce every detail of the epidemiological debate To communicate clinically actionable precautions resulting from the regulatory assessment To declare a causal relationship with greater certainty than the evidence supports To replace ongoing pharmacovigilance monitoring

Question 7 of 10 Which approach is most appropriate when epidemiological studies produce conflicting results?

Count positive studies and ignore study design Accept the largest study without examining its limitations Compare populations, comparators, exposure definitions, follow-up, confounding control and outcome ascertainment Treat all non-significant findings as evidence of no risk

Question 8 of 10 A very large administrative-database study lacks reliable information on smoking and diabetes severity. What is the most appropriate interpretation?

Its size automatically compensates for missing confounder information Its results may be precise statistically but still substantially biased Its findings should be accepted over all smaller studies Confounding is impossible when more than one million patients are included

Question 9 of 10 What is the main methodological concern when pioglitazone is preferentially prescribed to patients with more difficult-to-control diabetes?

Confounding by disease severity may make the drug appear associated with risk partly because of the patients receiving it Treatment duration becomes irrelevant in all analyses Randomisation bias is introduced into observational cohorts The comparator group will necessarily have more bladder cancer

Question 10 of 10 A patient developed bladder cancer after several years of pioglitazone treatment and had heavy prior smoking exposure. What is the strongest pharmacovigilance interpretation?

The drug caused the cancer because exposure preceded the diagnosis Smoking excludes any possible contribution from the drug The case is compatible with the signal but requires assessment of latency, cumulative exposure and competing causes The case cannot be relevant because individual cases never inform population signals

Historical Signal Evaluation: Pioglitazone and Bladder Cancer

Cookie Settings